finanzen.net
12.07.2019 17:15
Bewerten
(0)

Changing Paradigms in Clinical Trials Market, 2050 - Innovative Trial Designs, Real-world Evidence, Clinical Operations Management, Patient Centricity, Precision Medicine, Big Data, Blockchain

DRUCKEN

DUBLIN, July 12, 2019 /PRNewswire/ -- The "Changing Paradigms in Clinical Trials: Market Landscape and Competitive Insights, 2019-2050" report has been added to ResearchAndMarkets.com's offering.

The Changing Paradigms in Clinical Trials: Market Landscape and Competitive Insights, 2019-2050' report features an extensive study of the current landscape of industry players that are offering various types of innovative clinical research platforms/solutions to the pharmaceutical and life sciences industries.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future opportunity of the market for virtual clinical trial services, adaptive trial design services, real-world evidence-based clinical trial services and clinical operations management services.

Based on parameters, such as number of pre- or post-approval studies conducted annually, capital investments made in these studies, and the likely cost and time saving opportunities, we have provided an informed estimate of the likely evolution of the market for virtual clinical trials, adaptive trial designs, clinical operations management and real-world evidence-based clinical trials, in the short to mid-term and mid to long term, for the period 2019-2050.

The report also features the likely distribution of the current and forecasted opportunity across [A] different therapeutic areas (cardiovascular disorders, infectious disorders, metabolic disorders, neurological disorders, oncological disorders and others), [B] end-users (small-sized players, mid-sized players, large players and academia / others) [C] phase of development (phase I, phase II, phase III and phase IV) and [D] key geographical regions (US, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

Amongst other elements, the report features:

  • An overview of the current market landscape of companies offering solutions for virtual clinical trials, adaptive trial designs, clinical operations management and real-world evidence-based clinical trials, featuring information on year of establishment, geographical location, company size and type of offerings. It also includes a list of virtual clinical trials, clinical studies that have used/are using innovative designs (adaptive trials, basket trials and umbrella trials), and a case study on clinical trials being conducted in real-world settings; the studies are analyzed on the basis of various parameters, such as location of the trial site, target indication, trial phase and study start-date.
  • Brief profiles of companies offering solutions for virtual clinical trials, adaptive trial designs, clinical operations management and real-world evidence-based clinical trials, featuring information on their year of establishment, respective headquarters, company size, key executives, service/technology portfolio, recent developments and an informed future outlook.
  • A study of prevalent and emerging trends in the domain, as observed on the social media platform, Twitter. The analysis takes into consideration tweets posted on the platform, between 2013 and 2019 (till March), related to virtual trials, innovative trial designs and patient centricity.
  • A case study on the initiatives of big pharma players related to virtual clinical trials, offering insights on such clinical studies that have been conducted/planned by the aforementioned players, along with details on associated constraints and the future plans of players engaged in this domain.
  • An analysis of the investments made at various stages of development in companies that are focused in this area, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings.

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Existing Constraints in Clinical Research
3.2.1. Increasing Complexity and Cost of Trials
3.2.2. Evolving Regulatory Standards
3.2.3. Key Challenges in Patient Recruitment and Retention
3.2.4. Inefficient Data Handling
3.3. Emerging Trends in Clinical Research
3.3.1. Virtual Clinical Trials
3.3.2. Innovative Trial Designs
3.3.3. Real-world Evidence
3.3.4. Innovation in Clinical Operations Management
3.3.5. Patient Centricity
3.3.6. Precision Medicine
3.3.7. Big Data Analytics
3.3.8. Blockchain Technology

4. VIRTUAL CLINICAL TRIAL SERVICE PROVIDERS: CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Virtual Clinical Trial Service Providers: Overall Market Overview
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Geography
4.2.4. Analysis by Type of Service Offered
4.3. Virtual Clinical Trials: List of Ongoing/Completed Clinical Trials
4.3.1. Analysis by Study Start Year
4.3.2. Analysis by Phase of Development
4.3.3. Analysis by Study Type
4.3.4. Analysis by Study Status
4.3.5. Analysis by Location of Trial

5. ADAPTIVE TRIAL DESIGN SERVICE PROVIDERS: CURRENT MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Adaptive Trial Design Service Providers: Overall Market Overview
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Geography
5.2.4. Analysis by Type of Service Offered
5.3. Adaptive Clinical Trials: List of Ongoing/Completed Clinical Trials
5.4. Basket Clinical Trials: List of Ongoing/Completed Clinical Trials
5.5. Umbrella Clinical Trials: List of Ongoing/Completed Clinical Trials

6. REAL-WORLD EVIDENCE SERVICE PROVIDERS: CURRENT MARKET LANDSCAPE
6.1. Chapter Overview
6.2. RWE Service Providers: Overall Market Overview
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Geography
6.2.4. Analysis by Type of Service Offered
6.3. Case Study: Clinical Trials Conducted in Real-world Setting
6.4. Scope and Methodology
6.4.1. Analysis by Study Start Year
6.4.2. Analysis by Study Type
6.4.3. Analysis by Study Status
6.4.4. Analysis by Type of Sponsors/Collaborators
6.4.5. Most Active Players in Terms of Number of Trials
6.4.6. Analysis by Target Therapeutic Area
6.4.5. Analysis by Geography and Number of Clinical Trials
6.4.6. Analysis by Geography and Enrolled Patient Population

7. CLINICAL TRIAL OPERATIONS MANAGEMENT SERVICE PROVIDERS: CURRENT MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Clinical Trial Operations Management Service Providers: Overall Market Overview
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Geography
7.2.4. Analysis by Type of Service Offered

8. COMPANY PROFILES
8.1. Chapter Overview
8.2. Virtual Clinical Trial Service Providers
8.2.1. Center Point Clinical Services
8.2.2. eClinicalHealth
8.2.3. Mytrus (Medidata Solutions)
8.2.4. Science 37
8.3. Adaptive Trial Design Service Providers
8.3.1. Berry Consultants
8.3.2. CRF Bracket
8.3.3. Cytel
8.3.4. Evidera
8.4. RWE Service Providers
8.4.1. Clinerion
8.4.2. Medpace
8.4.3. NorthWest EHealth
8.4.4. TriNetX
8.5. Clinical Trial Operations Management Service Providers
8.5.1. endpoint Clinical
8.5.2. Greenphire
8.5.3. International Drug Development Institute (IDDI)
8.5.4. ThoughtSphere

9. EMERGING TRENDS ON SOCIAL MEDIA
9.1. Chapter Overview
9.2. Changing Paradigms in Clinical Trials: Trends on Twitter
9.2.1. Historical Trend in Volume of Tweets
9.2.2. Trending Words/Phrases on Twitter
9.3. Virtual Clinical Trials: Trends on Twitter
9.3.1. Historical Trend in Volume of Tweets
9.3.2. Cumulative Year-Wise Activity
9.3.3. Trending Words/Phrases on Twitter Related to Virtual Clinical Trials
9.3.4. Most Prolific Contributors on Twitter
9.4. Novel Trial Designs: Trends on Twitter
9.5. Patient Centricity: Trends on Twitter
9.6. Concluding Remarks

10. CASE STUDY: VIRTUAL CLINICAL TRIAL-RELATED INITIATIVES OF BIG PHARMA PLAYERS
10.1. Chapter Overview
10.2. Innovative Initiatives of Big Pharma Players
10.2.1. Pfizer
10.2.2. Johnson & Johnson
10.2.3. Sanofi
10.2.4. Novartis
10.2.5. GlaxoSmithKline
10.2.6. Amgen

11. FUNDING AND INVESTMENT ANALYSIS
11.1. Chapter Overview
11.2. Types of Funding
11.3. Changing Paradigms in Clinical Trials: Funding and Investment Analysis
11.3.1. Analysis by Number of Instances
11.3.2. Analysis by Amount Invested
11.3.3. Analysis by Type of Service Provider
11.3.4. Analysis by Type of Funding
11.3.5. Most Active Players
11.3.6. Most Active Investors
11.4. Concluding Remarks

12. MARKET OPPORTUNITY ASSESSMENT
12.1. Chapter Overview
12.2. Key Assumptions and Forecast Methodology
12.3. Virtual Clinical Trial Service Providers: Overall Market Opportunity, 2019- 2050
12.3.1. Virtual Clinical Trial Service Providers Market Opportunity: Distribution by Therapeutic Area, 2019-2050
12.3.2. Virtual Clinical Trials Service Providers Market Opportunity: Distribution by End-user, 2019-2050
12.3.3. Virtual Clinical Trials Service Providers Market Opportunity: Distribution by Phase of Development, 2019-2050
12.3.4. Virtual Clinical Trials Service Providers Market Opportunity: Distribution by Geography, 2019-2050

13. CONCLUSION

14. INTERVIEW TRANSCRIPTS
14.1. Chapter Overview
14.2. Andaman7
14.2.1. Interview Transcript: Phillipe Lemmens, Chief Operating Officer, Andaman7
14.3. ConsilX
14.3.1. Interview Transcript: Himanshu Verma, Founder and Chief Executive Officer, ConsilX & Rajesh Jain, Co-Founder, ConsilX
14.4. EmpiraMed
14.4.1. Interview Transcript: Greg Erman, President and Chief Executive Officer, EmpiraMed
14.5. uMotif
14.5.1. Interview Transcript: Jonathan Moshinsky, Head of Market Strategy, uMotif

15. APPENDIX 1: TABULATED DATA

16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

For more information about this report visit https://www.researchandmarkets.com/r/db7e6n

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content:http://www.prnewswire.com/news-releases/changing-paradigms-in-clinical-trials-market-2050---innovative-trial-designs-real-world-evidence-clinical-operations-management-patient-centricity-precision-medicine-big-data-blockchain-300883992.html

SOURCE Research and Markets

Anzeige
Anzeige
Börse Stuttgart Anlegerclub

Die richtige Strategie für die Börsenkrise

Stecken Sie nicht den Sand in den Kopf, sondern kaufen Sie die richtigen Aktien. Erfahren Sie im aktuellen Anlegermagazin mehr über attraktive Qualitätsaktien und zyklische Aktien
Kostenfrei registrieren und lesen!

Heute im Fokus

DAX beendet Handel höher -- US-Börsen mit leichtem Plus -- ams mit OSRAM-Gegenofferte -- Bayer-Strafe deutlich gesenkt -- Citigroup übertrifft Erwartungen -- Carl Zeiss Meditec, EVOTEC im Fokus

Moody's: BASF-Rating droht Herabstufung. Trump droht dem mit mauem Wachstum kämpfenden China mit neuen Zöllen. Milliardendeal zwischen Broadcom und Symantec angeblich geplatzt. OMV mit Millioneninvestition in Deutschland. Rheinmetall ergattert Großauftrag. Bitcoin rauscht unter 10.000 US-Dollar. Airbus-Aktie auf Rekordhoch.

Die 5 beliebtesten Top-Rankings

Promis
Diese Sternchen haben ihren eigenen Aktien-Index
Diese Aktien hat Warren Buffett im Depot
Die Änderungen unter den Top-Positionen
Die erfolgreichsten Kinofilme der letzten 25 Jahre
Welche Titel knackten die Milliardenmarke an den Kinokassen?
Das verdienen Aufsichtsratschefs in DAX-Konzernen
Deutlich unter Vorstandsgehältern
Apps & Social Media: Die wertvollsten Marken der Welt
Welche Marke macht das Rennen?
mehr Top Rankings

Umfrage

Wo sehen Sie den DAX Ende 2019?

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Wirecard AG747206
Deutsche Bank AG514000
Daimler AG710000
NEL ASAA0B733
Amazon906866
BayerBAY001
CommerzbankCBK100
BASFBASF11
Microsoft Corp.870747
Infineon AG623100
TeslaA1CX3T
Airbus SE (ex EADS)938914
Apple Inc.865985
EVOTEC SE566480
Deutsche Telekom AG555750